Evidence map›Paper›PMID 30291063›Full record

ArticleJMIR diabetes2017

Improving Glycemic Control With a Standardized Text-Message and Phone-Based Intervention: A Community Implementation.

Robert Mattson Peters, Matt Lui, Kunjan Patel, Lewis Tian, Kavon Javaherian, Eric Sink, Ran Xu, Zhuchen Xu, Wint Aung, Li Zhou and 6 more

Abstract read
In one paragraph

Article in JMIR diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Improving HbATelemedicine journal and e-health : the official journal of the American Telemedicine Association · 2020
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Robert Mattson Peters *Washington University in St. Louis School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0003-1828-0525
Matt Lui *Washington University in St. Louis School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0002-4981-8853
Kunjan PatelSaint Louis University School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0001-7094-9121
Lewis TianSaint Louis University School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0002-2479-7865
Kavon JavaherianWashington University in St. Louis School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0003-0317-5263
Eric SinkSaint Louis University School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0003-4922-485X
Ran XuWashington University in St. Louis School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0002-7576-1440
Zhuchen XuWashington University in St. Louis School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0001-5395-4463
Wint AungSaint Louis University School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0003-3372-9175
Li ZhouJohn Cochrane Division, VA Medical Center, St. Louis, MO, United States.ORCID http://orcid.org/0000-0002-1573-3181
Justin HuynhDivision of Internal Medicine, Mercy Clinic, St. Louis, MO, United States.ORCID http://orcid.org/0000-0001-6136-8317
Gregory PolitesWashington University in St. Louis School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0002-3276-668X
Melvin BlanchardWashington University in St. Louis School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0002-0965-7338
Avik SomWashington University in St. Louis School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0002-2198-7575
Will RossWashington University in St. Louis School of Medicine, St. Louis, MO, United States.ORCID http://orcid.org/0000-0002-8112-2979
Carlos Bernal-MizrachiDivision of Endocrinology, St. Louis VA Medical Service, St. Louis, MO, United States.ORCID http://orcid.org/0000-0002-8991-7522

Funding

VITAMIN D DEFICIENCY, INSULIN RESISTANCE AND CARDIOVASCULAR DISEASER01HL094818 · NHLBI · WASHINGTON UNIVERSITY · PI Carlos Bernal-Mizrachi · 2010 to 2026
$6.3M
NHLBI NIH HHS R01 HL094818
6 · The paper itself

Abstract

backgroundType II diabetes mellitus (T2DM) presents a major disease burden in the United States. Outpatient glycemic control among patients with T2DM remains difficult. Telemedicine shows great potential as an adjunct therapy to aid in glycemic control in real-world settings.

objectiveWe aimed to explore the effectiveness of EpxDiabetes, a novel digital health intervention, in improving hemoglobin A1c (HbA1c) and fasting blood glucose (FBG) among patients with uncontrolled diabetes.

methodsWe recruited 396 patients from a community clinic in St. Louis, Missouri, from a database of patients diagnosed with T2DM and with a most recent HbA1c >7% as part of a quality improvement project. An automated call or text-messaging system was used to monitor patient-reported FBG. If determined to be elevated, care managers were notified by email, text, or electronic medical record alert. Participants self-reported their FBG data by replying to EpxDiabetes automated phone calls or text messages. Data were subsequently analyzed, triaged, and shared with providers to enable appropriate follow-up and care plan adjustments. Absolute HbA1c reduction, patient engagement, and absolute patient-reported FBG reduction were examined at approximately 6 months post implementation.

resultsEpxDiabetes had an average 95.6% patient response rate to messages at least once per month and an average 71.1% response rate to messages at least once per week. Subsequent HbA1c drop with EpxDiabetes use over 4 months was -1.15% (95% CI -1.58 to -0.71) for patients with HbA1c >8% at baseline compared to the change in HbA1c over 4 months prior to the implementation of EpxDiabetes of only -0.005 points (95% CI -0.28 to 0.27), P=.0018.

conclusionsEpxDiabetes may help reduce HbA1c in patients with high HbA1c baselines (>8%). The intervention demonstrates high patient engagement sustainable for at least 6 months.

Indexed as

diabetes managementdiabetes mellituselectronic health (eHealth)glycemic controlmobile health (mHealth)SMStelehealthtelemedicine

Identifiers

PMID30291063
PMCPMC6238836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.